The Italian Competition Authority launches an investigation against a cartel allegedly carried out by two pharmaceutical companies (Roche, Novartis)

The Italian Competition Authority launches an investigation against a cartel allegedly carried out by Roche and Novartis in the pharmaceutical market (Roche Novartis) The facts of the case The Italian Competition Authority (ICA) has opened an Article 101 TFEU proceedings against Roche and Novartis [1], upon receipt of two complaints lodged by an association of private health care providers and by the Italian Ophthalmological Society, respectively. The complainants alleged that Roche and Novartis had concluded an agreement to prevent the off-label commercial use of Avastin to the benefit to the approved but more expensive Lucentis. Avastin is a drug patented by the US Roche subsidiary, Genentech, for the treatment of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Desogus Law Office (Cagliari)

Quotation

Michele Giannino, The Italian Competition Authority launches an investigation against a cartel allegedly carried out by two pharmaceutical companies (Roche, Novartis), 6 February 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 50997

Visites 404

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues